218 related articles for article (PubMed ID: 12490765)
1. Well differentiated thyroid cancer.
Kinder BK
Curr Opin Oncol; 2003 Jan; 15(1):71-7. PubMed ID: 12490765
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of differentiated carcinoma of the thyroid gland].
Mimura T; Ito K
Nihon Naika Gakkai Zasshi; 1997 Jul; 86(7):1184-9. PubMed ID: 9379097
[No Abstract] [Full Text] [Related]
3. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
4. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
5. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.
Sampson E; Brierley JD; Le LW; Rotstein L; Tsang RW
Cancer; 2007 Oct; 110(7):1451-6. PubMed ID: 17705176
[TBL] [Abstract][Full Text] [Related]
6. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group.
Hölzer S; Reiners C; Mann K; Bamberg M; Rothmund M; Dudeck J; Stewart AK; Hundahl SA
Cancer; 2000 Jul; 89(1):192-201. PubMed ID: 10897018
[TBL] [Abstract][Full Text] [Related]
7. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
[TBL] [Abstract][Full Text] [Related]
8. [Outcomes of long-term combined treatment in follicular thyroid carcinoma].
Baranauskas Z; Valuckas KP; Tiskevicius S
Medicina (Kaunas); 2010; 46(4):268-74. PubMed ID: 20571295
[TBL] [Abstract][Full Text] [Related]
9. Treatment of refractory thyroid cancer.
Berdelou A; Lamartina L; Klain M; Leboulleux S; Schlumberger M
Endocr Relat Cancer; 2018 Apr; 25(4):R209-R223. PubMed ID: 29371330
[TBL] [Abstract][Full Text] [Related]
10. Management of invasive and advanced thyroid cancer.
Favia G; Iacobone M; Zanella S; Ciarleglio FA
Minerva Endocrinol; 2009 Mar; 34(1):37-55. PubMed ID: 19209127
[TBL] [Abstract][Full Text] [Related]
11. Management of pediatric differentiated thyroid cancer: An overview for the pediatric oncologist.
Prasad PK; Mahajan P; Hawkins DS; Mostoufi-Moab S; Venkatramani R
Pediatr Blood Cancer; 2020 Jun; 67(6):e28141. PubMed ID: 32275118
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy for papillary and follicular thyroid carcinoma.
Klain M; Ricard M; Leboulleux S; Baudin E; Schlumberger M
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S479-85. PubMed ID: 12192549
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in well-differentiated thyroid carcinoma in patients treated and followed in the same institution.
Cappelli C; Pirola I; Braga M; De Martino E; Morassi ML; Gandossi E; Mattanza C; Balzano R; Castellano M; Rosei EA
Ann Ital Chir; 2006; 77(2):107-13. PubMed ID: 17147082
[TBL] [Abstract][Full Text] [Related]
15. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
[TBL] [Abstract][Full Text] [Related]
16. Impact of surgical resection extension on outcome for primary well-differentiated thyroid cancer-a retrospective analysis.
Muller S; Senne M; Kirschniak A; Königsrainer A; Bares R; Falch C
World J Surg Oncol; 2017 Oct; 15(1):190. PubMed ID: 29065879
[TBL] [Abstract][Full Text] [Related]
17. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
19. The role of total thyroidectomy in the management of differentiated thyroid cancer.
Stephenson BM; Wheeler MH; Clark OH
Curr Opin Gen Surg; 1994; ():53-9. PubMed ID: 7584009
[TBL] [Abstract][Full Text] [Related]
20. [Radioiodine in the treatment of generalized papillary and follicular thyroid carcinoma].
Mäenpää H
Duodecim; 2014; 130(6):573-9. PubMed ID: 24724456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
